МОМихаил Александрович Овчаров

Михаил Александрович Овчаров

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Михаил Александрович Овчаров has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COMPARATIVE ANALYSIS OF THE IMMEDIATE RESULTS OF CORRECTION OF SECONDARY TRICUSPID REGURGITATION BY VARIOUS TYPES OF SUPPORT RINGS ACCORDING TO THE DATA OF THE REGISTRY STUDY

    by Антон Валерьевич Сотников, Alexander N. Stasev, Alexey V. Yevtushenko, Alexander V. Bogachev-Prokofiev, Михаил Александрович Овчаров, Alexander S. Krikovtsov, Ольга Леонидовна Барбараш, Александр Сергеевич Криковцов

    HighlightsAn analysis of a register study involving patients with mitral and aortic valve defects of various etiologies with concomitant secondary tricuspid insufficiency is presented. All patients underwent correction of the primary affected valves, as well as secondary tricuspid valve insufficiency using support rings of various designs (semi-rigid, rigid and flexible). The results obtained demonstrate the comparable effectiveness of the rings used in terms of freedom from recurrence of tricuspid regurgitation in the early postoperative period, as well as hospital mortality. AbstractAim. To compare short-term outcomes of treatment of functional tricuspid regurgitation (TR) using annuloplasty rings of different types (flexible, semi-rigid and rigid) in patients who had undergone surgery for valvular defects.Methods. The two-center registry-based study included 708 patients with mitral or aortic valve defects and moderate or severe STR requiring surgical treatment. Exclusion criteria were as follows: organic tricuspid valve regurgitation, age below 18 years. Primary endpoints were as follows: in-hospital mortality, recurrent tricuspid regurgitation (> grade 2) in the early postoperative period.Results. Of the patients included in this study, 400 (56.4%) patients received a semi-rigid ring made by “NeoCor” (the NeoCor group), 154 (21.8%) patients received a flexible ring made by “MedInj” (the Flexible group), and 154 (21.8%) patients received a rigid ring made by “MedInj” (the Rigid group). Most patients presented with the clinical manifestations of chronic heart failure of The New York Heart Association (NYHA) functional class II/III. However, in the NeoCor group the majority of patients presented with (NYHA) functional class IV. Rheumatic valve disease prevailed in the NeoCor group, and connective tissue disorders prevailed in the Flexible and Rigid groups. Initially, in the NeoCor group, STR was marked by a predominance of severe regurgitation. The most frequently reported perioperative complications in the analyzed sample were the need for inotropic support for more than 24 hours, development of atrial fibrillation, hydro- or hemothorax, implantation of permanent pacemakers, prolonged mechanical ventilation. In-hospital mortality did not differ between the groups and amounted to 1.5% in the NeoCor group, 2.6% in the Flexible group and 1.9% in the Rigid group. Echocardiographic examination in the postoperative period did not reveal > grade 2 tricuspid regurgitation in any of the groups.Conclusion. According to the results of the study, semi-rigid, flexible and rigid annuloplasty rings are equally effective in treating functional TR.


  • Open Access

    Results of concomitant cryoablation for atrial fibrillation during mitral valve surgery

    by Alexander Bogachev-Prokophiev, Ravil Sharifulin, Anastasiia Karadzha, Sergey Zheleznev, Alexander Afanasyev, Mikhail Ovcharov, Alexey Pivkin, Anton Zalesov, Sergey Budagaev, Sergey Ivantsov, et al.

    Concomitant atrial fibrillation ablation during mitral valve (MV) surgery using radio frequency energy sources has been reported previously with excellent outcomes. However, data regarding the effectiveness of concomitant cryoablation remain limited. This study aimed to assess the efficacy of concomitant cryoablation in patients scheduled for MV surgery. Between 2012 and 2020, 242 adult patients who underwent MV surgery and concomitant cryoablation were included. Data on rhythm, medication status and clinical events were assessed at 3, 6 and 12 months, then annually thereafter. Early mortality was 0.4%. The mean follow-up period duration was 43.9 months. The survival rates at 1, 3 and 5 years were 97.3%, 94.3% and 87.7%, respectively. The rates of freedom from atrial arrhythmia paroxysms at 1, 3 and 5 years were 79.0%, 64.0% and 60.5%, respectively. Atrial arrhythmia recurrence was associated with isolated left atrial lesion set (P = 0.038), large right atrial size (P = 0.002), lower surgeon experience (P = 0.003) and atrial fibrillation paroxysms in the early postoperative period (P = 0.002). Concomitant cryoablation during MV surgery is a safe and reproducible technique. The procedure provides acceptable freedom from atrial arrhythmias recurrences during long-term follow-up. The biatrial lesion set has advantages over the left atrium pattern in terms of atrial arrhythmias freedom. Surgeon experience significantly influences atrial fibrillation ablation success. Randomized trials are needed to compare radiofrequency and cryoablation.


  • Open Access

    Meshalkin National Medical Research Center

    by A. V. Bogachev-Prokofiev, R. M. Sharifulin, D. A. Astapov, M. A. Ovcharov, M. A. Ovchinnikova, S. O. Lavinyukov, A. V. Sapegin, A. V. Afanasyev, S. I. Zheleznev, V. M. Nazarov, et al.

    We present three cases of successful transatrial transcatheter valve-in-valve implantation in patients with bioprosthetic mitral valve dysfunction. Patients with a high surgical risk, with severe heart failure due to bioprosthetic mitral valve dysfunction, were implanted with transcatheter prostheses using the transatrial approach.Transesophageal echocardiography and fluoroscopy-guided transcatheter mitral prosthetic valve positioning was performed. With a cardiac pacing at 180 bpm, a transcatheter valve was implanted. The transcatheter valves functioned properly after surgery. The patients were discharged in satisfactory condition.

  • Open Access

    The 2020 American Heart Association / American College of Cardiology guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: What is new?

    by С. А. Будагаев, А. В. Афанасьев, A.V. Bogachev-Prokophiev, А. С. Залесов, M.A. Ovcharov

    On 22 December 2020, Circulation published the new American College of Cardiology / American Heart Association guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. The most important guidelines were those concerning pharmacological and invasive methods of treating symptomatic patients with obstruction of the left ventricular outlet. Considering the most recent clinical studies, the indications for invasive methods of treatment have expanded to include septal myectomy and alcohol septal ablation. A separate section in the guidelines has been devoted to the management of non-obstructive hypertrophic cardiomyopathy with preserved left ventricular ejection fraction. The recommendations for patients with hypertrophic cardiomyopathy with atrial fibrillation, ventricular arrhythmias and severe heart failure have been revised. Received 26 March 2021. Revised 12 May 2021. Accepted 13 May 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. OvcharovDrafting the article: S.A. Budagaev, A.V. Afanasyev, A.S. ZalesovCritical revision of the article: A.V. Bogachev-ProkophievFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, A.S. Zalesov, M.A. Ovcharov


  • Open Access

    First experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis

    by A. V. Bogachev-Prokofiev, R. M. Sharifulin, M. A. Ovcharov, A. N. Pivkin, O. V. Krestyaninov, T. V. Antropova, M. A. Ovchinnikova, D. A. Astapov, A. V. Sapegin, A. V. Afanasyev, et al.

    We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.


  • Allografts and xenografts for right ventricular outflow tract reconstruction in Ross patients

    by Ravil Sharifulin, Alexander Bogachev-Prokophiev, Igor Demin, Alexander Afanasyev, Mikhail Ovcharov, Alexey Pivkin, Andrey Sapegin, Irina Zhuravleva, Alexander Karaskov

    OBJECTIVES: Pulmonary allografts (AG) are the gold standard for right ventricular outflow tract (RVOT) reconstruction during the Ross procedure. However, there is limited availability of AG in some countries, and the use of alternative grafts for RVOT reconstruction remains controversial. This study aimed to compare the rates of freedom from RVOT graft dysfunction for AG and diepoxide-treated pericardial xenografts (DPXG). METHODS: Between 1998 and 2015, 793 adult patients underwent the Ross procedure in our centre. Using propensity score matching, the clinical outcomes and echocardiographic results of AG and DPXG were compared. RESULTS: Propensity score matching resulted in 2 groups (AG and DPXG) of 122 patients each. No difference was found in early mortality (2.5%) in both groups. The freedom from RVOT graft dysfunction curves were comparable between the AG and DPXG groups (P = 0.186) and the 8-year rates of freedom from graft dysfunction were 91.8% and 82.2%, respectively. The survival rates at 8 years were 90.5% and 90.1%, and the rates of freedom from RVOT reintervention at 8 years were 100% and 96.8% for the AG and DPXG groups, respectively. At discharge and follow-up, transprosthetic gradients were significantly higher in the DPXG group. The rate of the RVOT gradient progression was also higher in the DPXG group than in the AG group (1.80 ± 0.06 vs 1.39 ± 0.04 mmHg/year, P < 0.001). CONCLUSIONS: There was no difference in freedom from RVOT graft dysfunction by 8 years when using AG and DPXG in adult Ross patients, nor in survival and freedom from RVOT conduit reintervention. Long-term results need further evaluation.


  • Open Access

    FLEXIBLE RINGS IN COMPARISON WITH RIGID RINGS IN THE TREATMENT OF FUNCTIONAL TRICUSPID INSUFFICIENCY: TWO DIFFERENT MODELS OF REVERSE REMODELING OF THE RIGHT HEART

    by M. A. Ovcharov, A. V. Bogachev-Prokofiev, D. A. Astapov, A. N. Pivkin, K. S. Malozemov, T. N. Podsosnikova, O. Yu. Malakhova, A. M. Karaskov

    Objective. To compare the models of reverse remodeling of the right heart after the tricuspid valve repair with rigid or flexible rings.Material and Methods. During the period from September, 2016 to February, 2018, 308 patients who had indications for intervention on the mitral valve and concomitant tricuspid insufficiency without significant differences in clinical status were randomized into two groups. Patients of both groups underwent intervention on the mitral valve with concomitant tricuspid valve repair by a rigid ring (Rigid group, n=154) or a flexible ring (Flex group, n=154)Results. The perioperative mortality rates were 2.0% in the Rigid group and 2.5% in the Flex group (p=0.504). There was no difference in the pacemaker implantation rate (5.1% vs. 2.6%, p=0.238). Freedom from tricuspid insufficiency recurrence at 12 months follow-up was comparable (96.7% in the Rigid group vs 96.1% in the Flex group, p=0.521). The global systolic function of the right ventricle (fractional change in area, FAC; ejection fraction, EF) significantly increased in both groups (pConclusion. Both types of the devises had low rates of recurrence of tricuspid insufficiency at the midterm follow-up and contributed to the restoration of the global systolic function of the right ventricle. However, the rigid rings due to their design fix the tricuspid valve annulus, which inevitably affects the regional systolic function. In perspective, the flexible rings can function without interfering with the restoration of the natural shape of the tricuspid valve annulus and its uniform contraction during the cardiac cycle, thus ensuring a significant increase in regional systolic function.